STOCK TITAN

CURIS (CRIS) SEC Filings

CRIS NASDAQ

Curis Inc. filings document the regulatory record of a biotechnology company focused on emavusertib (CA-4948) and related oncology-development activities. Form 8-K disclosures cover financial results, clinical and regulatory updates, material agreements, capital-structure matters and Nasdaq listing-compliance notices.

Proxy and other filings describe shareholder voting matters, authorized-share proposals, securities issuances tied to preferred stock and warrant instruments, equity incentive plans, executive compensation and governance procedures. The filing record also includes pro forma financial information related to the completed sale of the company’s interest in Curis Royalty, LLC.

Rhea-AI Summary

Curis, Inc. (CRIS) common stock is the subject of a Schedule 13G reporting 372,000 shares of shared beneficial ownership by Armistice Capital, LLC and Steven Boyd, equal to 5.57% of the class. Both report shared voting and dispositive power over 372,000 shares, and zero sole voting or dispositive power.

Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd. and exercises voting and investment power under an Investment Management Agreement. Steven Boyd, its managing member, may be deemed to beneficially own the shares. The Master Fund disclaims beneficial ownership based on its stated inability to vote or dispose of the shares under that agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
ownership
-
Rhea-AI Summary

CURIS, Inc. (CRIS) amendment reports that Nantahala Capital Management, LLC and its control persons Wilmot B. Harkey and Daniel Mack may each be deemed beneficial owners of the same 258,739 common shares, or 9.99% of the class as of September 30, 2026. They report shared voting and dispositive power over those shares and no sole voting or dispositive power. The reported amount includes 164,915 shares that may be acquired within 60 days through convertible securities. Blackwell Partners LLC - Series A, a fund advised by Nantahala, has rights to receive or direct dividends or sale proceeds from more than five percent of the outstanding shares beneficially owned by Nantahala.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
ownership
-
Rhea-AI Summary

CURIS, Inc. (CRIS) reports that Nantahala Capital Partners Limited Partnership may be deemed the beneficial owner of 108,143 shares of common stock as of September 30, 2026, equal to 4.328% of the class. The reported amount includes 73,600 shares that may be acquired within 60 days through exercise of securities. Nantahala reported shared voting and dispositive power over 108,143 shares and no sole voting or dispositive power. The percentage calculation cites 2,425,078 shares outstanding, based on 2,090,077 shares outstanding as of August 7, 2026, plus 335,001 shares issued in CURIS's offering that closed on or about August 14, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
ownership
Rhea-AI Summary

Curis, Inc. (CRIS) registered up to 33,333,360 common shares for resale by selling stockholders: 2,574,517 shares of common stock, 14,092,163 shares underlying October 2026 pre-funded warrants and 16,666,680 shares underlying October 2026 common warrants. The registration statement must become effective before sales; warrant shares may be offered only after exercise. Curis receives no proceeds from resales, but may receive cash proceeds from warrant exercises.

The pre-funded warrants are immediately exercisable at $0.01 per share. Common warrants are exercisable beginning April 19, 2027 at $0.60 per share and expire April 19, 2032. Beneficial-ownership limits are 4.99% or 9.99%, as applicable, and may be increased on 61 days’ notice but cannot exceed 19.99%. Curis’ 2025 audited financial statements include an explanatory paragraph concerning its ability to continue as a going concern.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
registration
-
Rhea-AI Summary

Curis, Inc. (CRIS) reported no revenue and a net loss of $8.120 million for the three months ended September 30, 2026, compared with revenue of $3.176 million and a net loss of $7.729 million a year earlier. For the first nine months, revenue was $0 versus $8.305 million, net loss was $40.900 million versus $26.938 million, and operating cash use was $24.396 million versus $20.830 million. The company said it lost Erivedge royalty revenue after selling Erivedge in November 2025.

Curis is focusing emavusertib development on a Phase 1/2 study in relapsed/refractory primary central nervous system lymphoma with ibrutinib and a Phase 2 chronic lymphocytic leukemia study with zanubrutinib; its acute myeloid leukemia studies are substantially complete. An October 2026 private placement generated approximately $7.5 million in net proceeds. Management said, together with $5.0 million in cash and cash equivalents as of September 30, this should fund existing operations into the first quarter of 2027, while cautioning that assumptions could prove wrong. Curis disclosed substantial doubt about its ability to continue as a going concern. On November 2, 2026, it received a Nasdaq delisting determination over the minimum bid price requirement and appealed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
quarterly report
-
Rhea-AI Summary

Curis, Inc. reported a third-quarter 2026 net loss of $8.120 million, compared with $7.729 million a year earlier, and a nine-month net loss of $40.900 million versus $26.938 million. It reported no revenue in the 2026 periods, following the 2025 sale of Erivedge royalties; revenue was $3.176 million for Q3 2025 and $8.305 million for the first nine months of 2025.

Curis said it is enrolling patients in two emavusertib combination studies. PCNSL data as of July 1, 2026 showed response rates of 26% (10 of 39) among all BTKi-experienced patients and 86% (6 of 7) among all BTK-naïve patients; among evaluable patients, rates were 33% (10 of 30) and 100% (5 of 5), respectively. The CLL study had enrolled 12 patients, with initial data expected in December 2026.

Cash and cash equivalents were $5.014 million as of September 30, 2026. Curis said cash plus approximately $7.5 million in net proceeds from its October 2026 private placement should fund existing operations into Q1 2027, while also stating that available cash was insufficient to support current operations within the next 12 months. It said substantial additional funding is required to develop emavusertib and support operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
current report
Rhea-AI Summary

Thomas A. Satterfield, Jr., the reporting person, reported beneficial ownership of 616,565 Curis, Inc. (CRIS) shares, or 8.8%. He reported 326,500 common shares and 290,065 warrants; the reported share amount assumes exercise of all listed warrants. The percentage is based on Curis’s 6,679,229 common shares outstanding as of October 26, 2026.

The warrants may not be exercised if doing so would cause Satterfield and his affiliates to exceed 9.99% beneficial ownership after the shares are issued. He reported sole voting and dispositive power over 131,725 shares and shared voting and dispositive power over 484,840 shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.39%
Tags
ownership
-
Rhea-AI Summary

Curis, Inc. received a Nasdaq staff determination letter on November 2, 2026, stating that its common stock had closed below the $1.00 per-share minimum bid price for 30 consecutive business days. Curis effected a 1-for-20 reverse stock split on July 6, 2026, and Nasdaq rules make the company ineligible for a compliance period after a reverse split within the prior year.

Curis is also subject to a one-year Discretionary Panel Monitor following a July 24, 2026 Panel decision. The company intends to request a new hearing, which will stay further delisting actions, but says there is no assurance the appeal will succeed or that it will remain listed on Nasdaq.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.04%
Tags
current report
-
Rhea-AI Summary

Curis, Inc. asks stockholders to approve amendments authorizing a reverse stock split of 1-for-5 to 1-for-12; the board would choose the ratio and decide whether to proceed. If approved, the board may implement it within six months after stockholder approval or abandon it. Curis says the proposal is intended to raise its share price to meet Nasdaq’s continued-listing price criteria.

Curis regained compliance with Nasdaq’s $1.00-per-share Bid Price Rule on July 24, 2026, and is subject to a Discretionary Panel Monitor until July 24, 2027. As of October 26, 2026, 6,679,229 common shares were outstanding and eligible to vote. At the virtual special meeting on November 18, 2026, stockholders will also consider adjournment to seek additional proxies if the reverse-split proposal lacks sufficient votes; the board recommends votes FOR both proposals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.17%
Tags
proxy
Rhea-AI Summary

Curis, Inc. is asking stockholders to approve a reverse stock split at a ratio from 1-for-5 to 1-for-12, with the board selecting the final ratio and deciding whether to proceed. Any amendment must be filed within six months of stockholder approval, and the board may abandon the split before filing or effectiveness. Curis says its primary aim is to raise the share price to meet Nasdaq’s continued-listing bid-price requirement. An illustrative table using figures as of October 20, 2026 lists 6,679,229 common shares before the split and 1,335,846 or 556,603 after a 1-for-5 or 1-for-12 split, respectively, before fractional-share adjustments. If implemented, fractional shares would be rounded up to the nearest whole share, with no cash paid.

The virtual special meeting is scheduled for November 18, 2026. The board recommends voting “FOR” both the reverse split and an adjournment proposal, which could allow more time to solicit proxies if votes for the split are insufficient. Each proposal requires a majority of votes cast, and a quorum is one-third of shares issued and outstanding and entitled to vote. Curis says it received a Delist Determination Letter on April 27, 2026, after 30 consecutive business days with its closing bid below $1.00, then regained compliance on July 24, 2026; a Discretionary Panel Monitor remains in place until July 24, 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
proxy

FAQ

How many CURIS (CRIS) SEC filings are available on StockTitan?

StockTitan tracks 80 SEC filings for CURIS (CRIS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for CURIS (CRIS)?

The most recent SEC filing for CURIS (CRIS) was filed on November 16, 2026.